A weight-loss research peptide. Live vendor vial prices, sorted lowest first.
For research use only. Not for human consumption. No health, dosing, or usage claims are made.
Retatrutide (Eli Lilly research code LY3437943) is an investigational peptide that acts on three gut/metabolic hormone receptors (GIP, GLP-1 and glucagon). It is being studied in clinical trials and is not an approved medicine. Material sold to laboratories under this name is a research chemical, not a finished drug product.
Retatrutide has no PubChem compound record yet, so its molecular formula and weight are not published from an authoritative chemistry database. The on-file CAS (2381089-83-2) appears in ChEMBL and WHO INN records.
Regulatory status: Retatrutide is investigational and is not FDA-approved; as of 2026 it remains in clinical development with no approval record in Drugs@FDA.
Typical vendor vial prices, Jul 2026. Exact prices load with verified listings.
| Vendor | Vial price | |
|---|---|---|
Simple Peptide | $0.05Best | View vendor › |
Precision Research Peptides | $0.13 | View vendor › |
Prime Lab Peptides | $0.16 | View vendor › |
Koi Peptides | $0.18 | View vendor › |
Protide Health | $0.20 | View vendor › |
BioInfinity Lab | $0.22 | View vendor › |
Kaia Peptides | $0.33 | View vendor › |
BioLongevity Labs | $0.50 | View vendor › |
Mile High Compounds | $1 | View vendor › |
PSPeptides | $3.60 | View vendor › |
Skye Peptides | $8.80 | View vendor › |
These are areas explored in the scientific literature and clinical trials; they are not health claims and do not indicate an approved use.
Planning a reconstitution? Use the calculator — it is math for handling a vial, not dosing.
Sources & further reading: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (PubMed) · Retatrutide — A Game Changer in Obesity Pharmacotherapy (NCBI PMC) · FDA — Drugs@FDA (no approval record for retatrutide)
How we source this ›